1
|
Ryan K, Bolaňos B, Smith M, Palde PB, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1. J Biol Chem 2021; 296:100251. [PMID: 33361107 PMCID: PMC7948648 DOI: 10.1074/jbc.ra120.016573] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 12/14/2020] [Accepted: 12/24/2020] [Indexed: 12/23/2022] Open
Abstract
Poly-ADP-ribosyltransferases play a critical role in DNA repair and cell death, and poly(ADP-ribosyl) polymerase 1 (PARP1) is a particularly important therapeutic target for the treatment of breast cancer because of its synthetic lethal relationship with breast cancer susceptibility proteins 1 and 2. Numerous PARP1 inhibitors have been developed, and their efficacy in cancer treatment is attributed to both the inhibition of enzymatic activity and their ability to trap PARP1 on to the damaged DNA, which is cytotoxic. Of the clinical PARP inhibitors, talazoparib is the most effective at trapping PARP1 on damaged DNA. Biochemically, talazoparib is also suspected to be a potent inhibitor of PARP5a/b (tankyrase1/2 [TNKS1/2]), which is an important regulator of Wnt/β-catenin pathway. Here we show using competition experiments in cell lysate that, at a clinically relevant concentration, talazoparib can potentially bind and engage TNKS1. Using surface plasmon resonance, we measured the dissociation constants of talazoparib, olaparib, niraparib, and veliparib for their interaction with PARP1 and TNKS1. The results show that talazoparib has strong affinity for PARP1 as well as uniquely strong affinity for TNKS1. Finally, we used crystallography and hydrogen deuterium exchange mass spectroscopy to dissect the molecular mechanism of differential selectivity of these PARP1 inhibitors. From these data, we conclude that subtle differences between the ligand-binding sites of PARP1 and TNKS1, differences in the electrostatic nature of the ligands, protein dynamics, and ligand conformational energetics contribute to the different pharmacology of these PARP1 inhibitors. These results will help in the design of drugs to treat Wnt/β-catenin pathway-related cancers, such as colorectal cancers.
Collapse
Affiliation(s)
- Kevin Ryan
- Structural Biology and Protein Science, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Ben Bolaňos
- Structural Biology and Protein Science, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Marissa Smith
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Prakash B Palde
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Paulina Delgado Cuenca
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Todd L VanArsdale
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Sherry Niessen
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Lianglin Zhang
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Douglas Behenna
- Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Martha A Ornelas
- Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Khanh T Tran
- Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Stephen Kaiser
- Structural Biology and Protein Science, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Lawrence Lum
- Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Al Stewart
- Structural Biology and Protein Science, Pfizer Worldwide Research and Development, San Diego, California, USA
| | - Ketan S Gajiwala
- Structural Biology and Protein Science, Pfizer Worldwide Research and Development, San Diego, California, USA.
| |
Collapse
|
2
|
Kung PP, Bingham P, Burke BJ, Chen Q, Cheng X, Deng YL, Dou D, Feng J, Gallego GM, Gehring MR, Grant SK, Greasley S, Harris AR, Maegley KA, Meier J, Meng X, Montano JL, Morgan BA, Naughton BS, Palde PB, Paul TA, Richardson P, Sakata S, Shaginian A, Sonnenburg WK, Subramanyam C, Timofeevski S, Wan J, Yan W, Stewart AE. Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library. ACS Med Chem Lett 2020; 11:1175-1184. [PMID: 32550998 DOI: 10.1021/acsmedchemlett.0c00029] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 04/10/2020] [Indexed: 11/29/2022] Open
Abstract
Two novel compounds were identified as Naa50 binders/inhibitors using DNA-encoded technology screening. Biophysical and biochemical data as well as cocrystal structures were obtained for both compounds (3a and 4a) to understand their mechanism of action. These data were also used to rationalize the binding affinity differences observed between the two compounds and a MLGP peptide-containing substrate. Cellular target engagement experiments further confirm the Naa50 binding of 4a and demonstrate its selectivity toward related enzymes (Naa10 and Naa60). Additional analogs of inhibitor 4a were also evaluated to study the binding mode observed in the cocrystal structures.
Collapse
Affiliation(s)
- Pei-Pei Kung
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Patrick Bingham
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Benjamin J. Burke
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Qiuxia Chen
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Xuemin Cheng
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Ya-Li Deng
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Dengfeng Dou
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Junli Feng
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Gary M. Gallego
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Michael R. Gehring
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Stephan K. Grant
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Samantha Greasley
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Anthony R. Harris
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Karen A. Maegley
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jordan Meier
- Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Xiaoyun Meng
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Jose L. Montano
- Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Barry A. Morgan
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
- HitGen Pharmaceuticals Inc., PO Box 88240, Houston, Texas 77288, United States
| | - Brigitte S. Naughton
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Prakash B. Palde
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Thomas A. Paul
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Paul Richardson
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sylvie Sakata
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Alex Shaginian
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - William K. Sonnenburg
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Chakrapani Subramanyam
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Sergei Timofeevski
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Jinqiao Wan
- HitGen Inc., Building 6, No.8, Huigu first East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan 610200, P.R. China
| | - Wen Yan
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| | - Albert E. Stewart
- Worldwide Research and Development, Pfizer Inc., 10770 Science Center Drive, San Diego, California 92121, United States
| |
Collapse
|
3
|
Paritala H, Palde PB, Carroll KS. Functional Site Discovery in a Sulfur Metabolism Enzyme by Using Directed Evolution. Chembiochem 2016; 17:1873-1878. [PMID: 27411165 DOI: 10.1002/cbic.201600264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Indexed: 11/07/2022]
Abstract
In human pathogens, the sulfate assimilation pathway provides reduced sulfur for biosynthesis of essential metabolites, including cysteine and low-molecular-weight thiol compounds. Sulfonucleotide reductases (SRs) catalyze the first committed step of sulfate reduction. In this reaction, activated sulfate in the form of adenosine-5'-phosphosulfate (APS) or 3'-phosphoadenosine 5'-phosphosulfate (PAPS) is reduced to sulfite. Gene knockout, transcriptomic and proteomic data have established the importance of SRs in oxidative stress-inducible antimicrobial resistance mechanisms. In previous work, we focused on rational and high-throughput design of small-molecule inhibitors that target the active site of SRs. However, another critical goal is to discover functionally important regions in SRs beyond the traditional active site. As an alternative to conservation analysis, we used directed evolution to rapidly identify functional sites in PAPS reductase (PAPR). Four new regions were discovered that are essential to PAPR function and lie outside the substrate binding pocket. Our results highlight the use of directed evolution as a tool to rapidly discover functionally important sites in proteins.
Collapse
Affiliation(s)
- Hanumantharao Paritala
- Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 2B2, Jupiter, FL, 33458, USA
| | - Prakash B Palde
- Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 2B2, Jupiter, FL, 33458, USA
| | - Kate S Carroll
- Department of Chemistry, The Scripps Research Institute, 130 Scripps Way, 2B2, Jupiter, FL, 33458, USA.
| |
Collapse
|
4
|
Truong TH, Ung PMU, Palde PB, Paulsen CE, Schlessinger A, Carroll KS. Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase. Cell Chem Biol 2016; 23:837-848. [PMID: 27427230 DOI: 10.1016/j.chembiol.2016.05.017] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 05/17/2016] [Accepted: 05/30/2016] [Indexed: 12/19/2022]
Abstract
Epidermal growth factor receptor (EGFR) is a target of signal-derived H2O2, and oxidation of active-site cysteine 797 to sulfenic acid enhances kinase activity. Although a major class of covalent drugs targets C797, nothing is known about its catalytic importance or how S-sulfenylation leads to activation. Here, we report the first detailed functional analysis of C797. In contrast to prior assumptions, mutation of C797 diminishes catalytic efficiency in vitro and cells. The experimentally determined pKa and reactivity of C797 toward H2O2 correspondingly distinguish this residue from the bulk of the cysteinome. Molecular dynamics simulation of reduced versus oxidized EGFR, reinforced by experimental testing, indicates that sulfenylation of C797 allows new electrostatic interactions to be formed with the catalytic loop. Finally, we show that chronic oxidative stress yields an EGFR subpopulation that is refractory to the FDA-approved drug afatinib. Collectively, our data highlight the significance of redox biology to understanding kinase regulation and drug pharmacology.
Collapse
Affiliation(s)
- Thu H Truong
- Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA; Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Peter Man-Un Ung
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Prakash B Palde
- Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Candice E Paulsen
- Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA
| | - Avner Schlessinger
- Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Kate S Carroll
- Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
| |
Collapse
|
5
|
Palde PB, Bhaskar A, Pedró Rosa LE, Madoux F, Chase P, Gupta V, Spicer T, Scampavia L, Singh A, Carroll KS. First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating M. tuberculosis. ACS Chem Biol 2016; 11:172-84. [PMID: 26524379 DOI: 10.1021/acschembio.5b00517] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Development of effective therapies to eradicate persistent, slowly replicating M. tuberculosis (Mtb) represents a significant challenge to controlling the global TB epidemic. To develop such therapies, it is imperative to translate information from metabolome and proteome adaptations of persistent Mtb into the drug discovery screening platforms. To this end, reductive sulfur metabolism is genetically and pharmacologically implicated in survival, pathogenesis, and redox homeostasis of persistent Mtb. Therefore, inhibitors of this pathway are expected to serve as powerful tools in its preclinical and clinical validation as a therapeutic target for eradicating persisters. Here, we establish a first functional HTS platform for identification of APS reductase (APSR) inhibitors, a critical enzyme in the assimilation of sulfate for the biosynthesis of cysteine and other essential sulfur-containing molecules. Our HTS campaign involving 38 350 compounds led to the discovery of three distinct structural classes of APSR inhibitors. A class of bioactive compounds with known pharmacology displayed potent bactericidal activity in wild-type Mtb as well as MDR and XDR clinical isolates. Top compounds showed markedly diminished potency in a conditional ΔAPSR mutant, which could be restored by complementation with Mtb APSR. Furthermore, ITC studies on representative compounds provided evidence for direct engagement of the APSR target. Finally, potent APSR inhibitors significantly decreased the cellular levels of key reduced sulfur-containing metabolites and also induced an oxidative shift in mycothiol redox potential of live Mtb, thus providing functional validation of our screening data. In summary, we have identified first-in-class inhibitors of APSR that can serve as molecular probes in unraveling the links between Mtb persistence, antibiotic tolerance, and sulfate assimilation, in addition to their potential therapeutic value.
Collapse
Affiliation(s)
- Prakash B. Palde
- Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Ashima Bhaskar
- Department
of Microbiology and Cell Biology (MCBL), Center for Infectious Disease
Research (CIDR), Indian Institute of Science (IISc.), Bangalore 560012, India
| | - Laura E. Pedró Rosa
- Lead
Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Franck Madoux
- Lead
Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Peter Chase
- Lead
Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Vinayak Gupta
- Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Timothy Spicer
- Lead
Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Louis Scampavia
- Lead
Identification Division, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Amit Singh
- Department
of Microbiology and Cell Biology (MCBL), Center for Infectious Disease
Research (CIDR), Indian Institute of Science (IISc.), Bangalore 560012, India
| | - Kate S. Carroll
- Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States
| |
Collapse
|
6
|
|
7
|
Palde PB, Jamison TF. Safe and Efficient Tetrazole Synthesis in a Continuous-Flow Microreactor. Angew Chem Int Ed Engl 2011; 50:3525-8. [DOI: 10.1002/anie.201006272] [Citation(s) in RCA: 109] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2010] [Revised: 02/09/2011] [Indexed: 11/06/2022]
|
8
|
Palde PB, Ofori LO, Gareiss PC, Lerea J, Miller BL. Strategies for recognition of stem-loop RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence. J Med Chem 2010; 53:6018-27. [PMID: 20672840 DOI: 10.1021/jm100231t] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Production of the Gag-Pol polyprotein in human immunodeficiency virus (HIV) requires a -1 ribosomal frameshift, which is directed by a highly conserved RNA stem-loop. Building on our discovery of a set of disulfide-containing peptides that bind this RNA, we describe medicinal chemistry efforts designed to begin to understand the structure-activity relationships and RNA sequence-selectivity relationships associated with these compounds. Additionally, we have prepared analogues incorporating an olefin or saturated hydrocarbon bioisostere of the disulfide moiety, as a first step toward enhancing biostability. The olefin-containing compounds exhibit affinity comparable to the lead disulfide and, importantly, have no discernible toxicity when incubated with human fibroblasts at concentrations up to 1 mM.
Collapse
Affiliation(s)
- Prakash B Palde
- Department of Dermatology, University of Rochester, Rochester, NY 14642, USA
| | | | | | | | | |
Collapse
|
9
|
Gareiss PC, Sobczak K, McNaughton BR, Palde PB, Thornton CA, Miller BL. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc 2008; 130:16254-61. [PMID: 18998634 PMCID: PMC2645920 DOI: 10.1021/ja804398y] [Citation(s) in RCA: 160] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy in adults, is an RNA-mediated disease. Dramatically expanded (CUG) repeats accumulate in nuclei and sequester RNA-binding proteins such as the splicing regulator MBNL1. We have employed resin-bound dynamic combinatorial chemistry (RBDCC) to identify the first examples of compounds able to inhibit MBNL1 binding to (CUG) repeat RNA. Screening an RBDCL with a theoretical diversity of 11 325 members yielded several molecules with significant selectivity for binding to (CUG) repeat RNA over other sequences. These compounds were also able to inhibit the interaction of GGG-(CUG)(109)-GGG RNA with MBNL1 in vitro, with K(i) values in the low micromolar range.
Collapse
Affiliation(s)
- Peter C. Gareiss
- Department of Biochemistry and Biophysics, University of Rochester, Rochester, New York 14642
- The Center for Future Health, University of Rochester, Rochester, New York 14642
| | - Krzysztof Sobczak
- Department of Neurology, University of Rochester, Rochester, New York 14642
| | - Brian R. McNaughton
- Department of Chemistry, University of Rochester, Rochester, New York 14642
- The Center for Future Health, University of Rochester, Rochester, New York 14642
| | - Prakash B. Palde
- Department of Biochemistry and Biophysics, University of Rochester, Rochester, New York 14642
- The Center for Future Health, University of Rochester, Rochester, New York 14642
| | | | - Benjamin L Miller
- Department of Dermatology, University of Rochester, Rochester, New York 14642
- Department of Biochemistry and Biophysics, University of Rochester, Rochester, New York 14642
- The Center for Future Health, University of Rochester, Rochester, New York 14642
| |
Collapse
|
10
|
Affiliation(s)
- Prakash B. Palde
- Department of Biochemistry and Biophysics and Department of Dermatology, University of Rochester, Rochester, New York 14642
| | - Peter C. Gareiss
- Department of Biochemistry and Biophysics and Department of Dermatology, University of Rochester, Rochester, New York 14642
| | - Benjamin L. Miller
- Department of Biochemistry and Biophysics and Department of Dermatology, University of Rochester, Rochester, New York 14642
| |
Collapse
|
11
|
Gareiss PC, Palde PB, Hubbard RD, Miller BL. Conformational and Structural Analysis of ater-Cyclopentane Scaffold for Molecular Recognition. European J Org Chem 2007. [DOI: 10.1002/ejoc.200600807] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Monga V, Nayyar A, Vaitilingam B, Palde PB, Jhamb SS, Kaur S, Singh PP, Jain R. Ring-substituted quinolines. Part 2: Synthesis and antimycobacterial activities of ring-substituted quinolinecarbohydrazide and ring-substituted quinolinecarboxamide analogues. Bioorg Med Chem 2004; 12:6465-72. [PMID: 15556764 DOI: 10.1016/j.bmc.2004.09.017] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2004] [Revised: 09/14/2004] [Accepted: 09/14/2004] [Indexed: 11/21/2022]
Abstract
Additional structural modifications of the new chemical entity, 2,8-dicyclopentyl-4-methylquinoline (DCMQ; MIC=6.25 microg/mL, M. tuberculosis H37Rv) resulted in the synthesis of four new series of the ring-substituted quinolinecarbohydrazides (series 1-4) constituting 22 analogues. All new derivatives were evaluated for in vitro antimycobacterial activities against drug-sensitive M. tuberculosis H37Rv strain. Certain ring-substituted-2-quinolinecarbohydrazide analogues described herein showed good inhibitory activity. In particular, analogues 4-(1-adamantyl)-2-quinolinecarbohydrazide (2d), 4,5-dicyclopentyl-2-quinolinecarbohydrazide (2e), 4,8-dicyclopentyl-2-quinolinecarbohydrazide (2f), and 4,5-dicyclohexyl-2-quinolinecarbohydrazide (2g) have exhibited the MIC value of 6.25 microg/mL. Further investigation of the most suitable lead prototype, 4-(1-adamantyl)-2-quinolinecarbohydrazide (2d, series 1) led to the synthesis of N2-alkyl/N2,N2-dialkyl/N2-aryl-4-(1-adamantyl)-2-quinolinecarboxamides (series 5) consisting of 13 analogues. Some of the synthesized carboxamides 7a, 7h, and 7m reported herein have exhibited excellent antimycobacterial activities in the range of 6.25-3.125 microg/mL against drug-sensitive and drug-resistant M. tuberculosis H37Rv strains.
Collapse
Affiliation(s)
- Vikramdeep Monga
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Vaitilingam B, Nayyar A, Palde PB, Monga V, Jain R, Kaur S, Singh PP. Synthesis and antimycobacterial activities of ring-substituted quinolinecarboxylic acid/ester analogues. Part 1. Bioorg Med Chem 2004; 12:4179-88. [PMID: 15246094 DOI: 10.1016/j.bmc.2004.05.018] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2004] [Revised: 05/14/2004] [Accepted: 05/14/2004] [Indexed: 10/26/2022]
Abstract
Structural optimization of recently discovered new chemical entity, 2,8-dicyclopentyl-4-methylquinoline (DCMQ; MIC= 6.25 microg/mL, M. tuberculosis H37Rv) resulted in the synthesis of four new series of ring-substituted quinolinecarboxylic acids/esters constituting 45 analogues. All new derivatives were evaluated for in vitro antimycobacterial activities against M. tuberculosis H37Rv. Certain ring-substituted-2-quinolinecarboxylic acid ester and ring-substituted-2-quinoline acetic acid ester analogues described herein showed moderate to good inhibitory activity. In particular, three analogues methyl 4,5-dicyclopentyl-2-quinolinecarboxylate (3b), methyl 4,8-dicyclopentyl-2-quinolinecarboxylate (3c) and ethyl 2-(2,8-dicyclopentyl-4-quinolyl)acetate (14g) exhibited excellent MIC values of 1.00, 2.00 and 4.00microg/mL, respectively. Results obtained indicate that substitution of the quinoline ring with dicyclopentyl substituent presumably enhances the antimycobacterial activities in the quinoline analogues described herein.
Collapse
Affiliation(s)
- Balasubramanian Vaitilingam
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar, Punjab 160 062, India
| | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
We report synthesis and anti-tuberculosis activities of a series of novel ring-substituted quinolines. The most effective compound of the series 3d (MIC=6.25 microg/mL, Mycobacterium tuberculosis H37Rv strain) was synthesized in one step; thus is an attractive lead molecule for anti-tuberculosis drug development. The results of this study represent the discovery of ring-substituted 4-methylquinolines as new class of potential anti-tuberculosis agents.
Collapse
Affiliation(s)
- Rahul Jain
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India.
| | | | | | | |
Collapse
|